Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC

Tina Cascone MD Of The University of Texas MD Anderson Cancer Center Discusses Results Of NEOSTAR Study: Study Looked At Neoadjuvant Nivolumab Or Nivolumab Plus Ipilimumab For Resectable NSCLC.<br /><br /><br /><br />... Author: Annual-Meeting Added: 06/06/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts